Kite Pharma

Views & Analysis
Vas Naramsimhan

Interview: Vas Narasimhan on Novartis' goal to lead in CAR-T...

Novartis’ head of drug development talks about its stake in CAR-T immunotherapy. These cell therapies are set to transform treatment of blood cancers – but questions about safety, manufacturing and cost versus clinical value remain